

Date: 03 May, 2025

To,
Corporate relationship Department,
BSE Limited,
1st Floor, Rotunda Building
P.J Towers Dalal Street, Fort,
Mumbai 400001

National Stock Exchange of India, Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block, Bandra-Kurla Complex,
Bandra (E),
Mumbai 400051

Stock Code: BSE – 530549 / NSE – SHILPAMED

Dear Sir/Ma'am,

**Ref: Europe (AGES, Austria) Inspection of Shilpa Biologicals Pvt Ltd (SBPL), a wholly owned subsidiary of
Shilpa Medicare Ltd**

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Shilpa Medicare's Biologics arm **Shilpa Biologicals** site at Dharwad, Karnataka, has received its European GMP certification for manufacturing of test batches based on the inspection between 18 Feb to 20 Feb 2025, conducted by the competent authority of Austria. The inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572.

Dr. Sridevi Khambhampaty, CEO of Shilpa Biologicals commented "This inspection outcome affirms our commitment to global quality standards and assures reliable outcomes for our customers."

About Shilpa Medicare: Shilpa Medicare is a leading global pharmaceutical company specializing in contract development and manufacturing services for small and large molecules. With a strong emphasis on oncology and a growing presence in biologics, the company offers comprehensive solutions from discovery to commercial supply. Shilpa Medicare operates world-class R&D and manufacturing facilities, serving partners across North America, Europe, and Asia.

For SHILPA MEDICARE LIMITED

Ritu Tiwary
Company Secretary & Compliance Officer